PCA3 and pachyonychia congenita: So far, the most well studied EV-enclosed lncRNA is PCA3, which has been shown to differentiate between PC patients and healthy males as well as between PC patients with GS ≤ 6 and GS ≥ 7 tumors (Ramirez-Garrastacho et al., 2022a) and is included in the FDA approved ExoDx PC test that informs whether to proceed with prostate biopsy in men with a PSA levels between 2 and 10 ng/mL (Tutrone et al., 2020).